Spring Bank Pharmaceuticals Reports First Quarter 2019 Financial and Operational Results and Provides Corporate Update
ACHIEVE trial completed – inarigivir HBsAg reduction comparable to interferon but with significantly better tolerability profile Phase 2 co-administration study of inarigivir + nucleotide analogue fully enrolled – top-line results expected 2H’19 Study …
Read more